Arrestin Beta-2 in Prostate Cancer and its Relationship with Trace Elements

Background: Prostate cancer (PCa) is the most prevalent non-cutaneous malignancy and the second-leading cause of cancer-relatedmortality among males. Cancer is just one of the several disorders that may be linked to variations in trace element concentrations.Objective: To evaluate serum arrestin β-2 as a prostate cancer tumor marker and its association with trace elements.Methods: This case- control study was carried out at the Department of Biochemistry, College of Medicine, University of Baghdad and at the Urology department, Ghazi Al-Hariri Hospital for Surgical Specialities during the period from March 2022 to May 2023. In this case-control study 120 males were enrolled: Sixty men with newly diagnosed primary prostate cancer (PCa) and 60 healthy men as controls. Blood samples were tested for arrestin β-2 levels using an enzyme-linked immunosorbent assay (ELISA), and trace element levels, including Zinc, Copper, and Manganese, were measured using a flame atomic absorption spectrophotometer.Results: Arrestin β-2 levels differed significantly between the control group and PCa patients. The serum copper level was significantly higher in the cases than in the controls. Zinc and manganese levels were significantly higher in the controls compared to the patients.Conclusion: It can be concluded that high arrestin β-2 and Copper levels and low Zinc and Manganese levels may serve as potential biomarkers for patients with prostatic Adenocarcinoma.